ÿþ<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:x="urn:schemas-microsoft-com:office:excel" xmlns:p="urn:schemas-microsoft-com:office:powerpoint" xmlns:a="urn:schemas-microsoft-com:office:access" xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882" xmlns:s="uuid:BDC6E3F0-6DA3-11d1-A2A3-00AA00C14882" xmlns:rs="urn:schemas-microsoft-com:rowset" xmlns:z="#RowsetSchema" xmlns:b="urn:schemas-microsoft-com:office:publisher" xmlns:ss="urn:schemas-microsoft-com:office:spreadsheet" xmlns:c="urn:schemas-microsoft-com:office:component:spreadsheet" xmlns:odc="urn:schemas-microsoft-com:office:odc" xmlns:oa="urn:schemas-microsoft-com:office:activation" xmlns:html="http://www.w3.org/TR/REC-html40" xmlns:q="http://schemas.xmlsoap.org/soap/envelope/" xmlns:rtc="http://microsoft.com/officenet/conferencing" xmlns:D="DAV:" xmlns:Repl="http://schemas.microsoft.com/repl/" xmlns:mt="http://schemas.microsoft.com/sharepoint/soap/meetings/" xmlns:x2="http://schemas.microsoft.com/office/excel/2003/xml" xmlns:ppda="http://www.passport.com/NameSpace.xsd" xmlns:ois="http://schemas.microsoft.com/sharepoint/soap/ois/" xmlns:dir="http://schemas.microsoft.com/sharepoint/soap/directory/" xmlns:ds="http://www.w3.org/2000/09/xmldsig#" xmlns:dsp="http://schemas.microsoft.com/sharepoint/dsp" xmlns:udc="http://schemas.microsoft.com/data/udc" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:sub="http://schemas.microsoft.com/sharepoint/soap/2002/1/alerts/" xmlns:ec="http://www.w3.org/2001/04/xmlenc#" xmlns:sp="http://schemas.microsoft.com/sharepoint/" xmlns:sps="http://schemas.microsoft.com/sharepoint/soap/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:udcs="http://schemas.microsoft.com/data/udc/soap" xmlns:udcxf="http://schemas.microsoft.com/data/udc/xmlfile" xmlns:udcp2p="http://schemas.microsoft.com/data/udc/parttopart" xmlns:wf="http://schemas.microsoft.com/sharepoint/soap/workflow/" xmlns:dsss="http://schemas.microsoft.com/office/2006/digsig-setup" xmlns:dssi="http://schemas.microsoft.com/office/2006/digsig" xmlns:mdssi="http://schemas.openxmlformats.org/package/2006/digital-signature" xmlns:mver="http://schemas.openxmlformats.org/markup-compatibility/2006" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns:mrels="http://schemas.openxmlformats.org/package/2006/relationships" xmlns:spwp="http://microsoft.com/sharepoint/webpartpages" xmlns:ex12t="http://schemas.microsoft.com/exchange/services/2006/types" xmlns:ex12m="http://schemas.microsoft.com/exchange/services/2006/messages" xmlns:pptsl="http://schemas.microsoft.com/sharepoint/soap/SlideLibrary/" xmlns:spsl="http://microsoft.com/webservices/SharePointPortalServer/PublishedLinksService" xmlns:Z="urn:schemas-microsoft-com:" xmlns:st="&#1;" xmlns="http://www.w3.org/TR/REC-html40"> <header></header> <head> <meta http-equiv=Content-Type content="text/html; charset=unicode"> <meta name=ProgId content=Word.Document> <meta name=Generator content="Microsoft Word 12"> <meta name=Originator content="Microsoft Word 12"> <link rel=File-List href="New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20(etanercept)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/filelist.xml"> <link rel=Edit-Time-Data href="New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20(etanercept)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/editdata.mso"> <!--[if !mso]> <style> v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} </style> <![endif]--><!--[if gte mso 9]><xml> <o:DocumentProperties> <o:Author>MooreH</o:Author> <o:Template>NormalEmail</o:Template> <o:Revision>1</o:Revision> <o:TotalTime>0</o:TotalTime> <o:Created>2010-03-01T11:55:00Z</o:Created> <o:Pages>1</o:Pages> <o:Words>1747</o:Words> <o:Characters>9961</o:Characters> <o:Company>rcpi</o:Company> <o:Lines>83</o:Lines> <o:Paragraphs>23</o:Paragraphs> <o:CharactersWithSpaces>11685</o:CharactersWithSpaces> <o:Version>12.00</o:Version> </o:DocumentProperties> </xml><![endif]--> <link rel=themeData href="New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20(etanercept)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/themedata.thmx"> <link rel=colorSchemeMapping href="New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20(etanercept)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/colorschememapping.xml"> <!--[if gte mso 9]><xml> <w:WordDocument> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:DoNotExpandShiftReturn/> <w:BreakWrappedTables/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--> <style> <!-- /* Font Definitions */ @font-face {font-family:"MS Mincho"; panose-1:2 2 6 9 4 2 5 8 3 4; mso-font-alt:"-ÿ3ÿ fg"; mso-font-charset:128; mso-generic-font-family:modern; mso-font-pitch:fixed; mso-font-signature:-1610612033 1757936891 16 0 131231 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1610611985 1073750139 0 0 159 0;} @font-face {font-family:Shaker2Lancet-Bold; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:0; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Univers-CondensedLight; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:0; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:"\@MS Mincho"; panose-1:2 2 6 9 4 2 5 8 3 4; mso-font-charset:128; mso-generic-font-family:modern; mso-font-pitch:fixed; mso-font-signature:-1610612033 1757936891 16 0 131231 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText {mso-style-noshow:yes; mso-style-priority:99; mso-style-link:"Footnote Text Char"; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} a:link, span.MsoHyperlink {mso-style-priority:99; color:blue; text-decoration:underline; text-underline:single;} p {mso-style-noshow:yes; mso-style-priority:99; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} span.FootnoteTextChar {mso-style-name:"Footnote Text Char"; mso-style-noshow:yes; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:"Footnote Text"; font-family:"Calibri","sans-serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} /* Page Definitions */ @page {mso-footnote-separator:url("New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20\(etanercept\)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/header.htm") fs; mso-footnote-continuation-separator:url("New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20\(etanercept\)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/header.htm") fcs; mso-endnote-separator:url("New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20\(etanercept\)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/header.htm") es; mso-endnote-continuation-separator:url("New%20data%20demonstrate%20early%20treatment%20with%20a%20combination%20of%20Enbrel%20\(etanercept\)%20and%20methotrexate%20can%20prevent%20rheumatoid%20arthritis%20progression%20with%20sustained%20remission%20at%20two%20years_files/header.htm") ecs;} @page Section1 {size:612.0pt 792.0pt; margin:72.0pt 72.0pt 72.0pt 72.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.Section1 {page:Section1;} --> </style> <!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} </style> <![endif]--> </head> <body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'> <div class=Section1> <p class=MsoNormal style='margin-left:135.0pt;text-indent:-135.0pt;tab-stops: 135.0pt;mso-layout-grid-align:none;text-autospace:none'><b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>From:<span style='mso-tab-count:1'>                                   </span></span></b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>ben.coomer@prnewswire.co.uk<o:p></o:p></span></p> <p class=MsoNormal style='margin-left:135.0pt;text-indent:-135.0pt;tab-stops: 135.0pt;mso-layout-grid-align:none;text-autospace:none'><b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>Sent:<span style='mso-tab-count:1'>                                    </span></span></b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>26 February 2010 06:02<o:p></o:p></span></p> <p class=MsoNormal style='margin-left:135.0pt;text-indent:-135.0pt;tab-stops: 135.0pt;mso-layout-grid-align:none;text-autospace:none'><b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>To:<span style='mso-tab-count:1'>                                        </span></span></b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>Helen Moore<o:p></o:p></span></p> <p class=MsoNormal style='margin-left:135.0pt;text-indent:-135.0pt;tab-stops: 135.0pt;mso-layout-grid-align:none;text-autospace:none'><b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>Subject:<span style='mso-tab-count:1'>                                </span></span></b><span style='font-family:"Calibri","sans-serif";mso-bidi-font-family:Calibri; color:black'>New data demonstrate early treatment with a combination of Enbrel® (etanercept) and methotrexate can prevent rheumatoid arthritis progression with sustained remission at two years<o:p></o:p></span></p> <p class=MsoNormal><o:p>&nbsp;</o:p></p> <p><span style='font-family:"Arial","sans-serif"'>&nbsp;</span></p> <p class=MsoNormal align=center style='text-align:center;line-height:200%'><b style='mso-bidi-font-weight:normal'>New data demonstrate early treatment with a combination of <st1:personname u1:st="on">Enbrel<sup></st1:personname>®</sup> (etanercept) and methotrexate can prevent rheumatoid arthritis progression with sustained remission at two years</b><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:200%'><b style='mso-bidi-font-weight: normal'><i><span style='color:red'><u2:p></u2:p>FOR HEALTHCARE PROFESSIONAL MEDIA ONLY</span></i></b><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:200%'><b style='mso-bidi-font-weight: normal'><i><span style='color:red'><u2:p>&nbsp;</u2:p></span></i></b></p> <p class=MsoNormal style='line-height:200%'><b style='mso-bidi-font-weight: normal'><span style='mso-bidi-font-family:Arial'>Friday, 26th February 2010:</span></b><span style='mso-bidi-font-family:Arial;mso-bidi-font-weight:bold'> </span><span style='color:black'>New data from the COMET trial, published today in <i>Arthritis &amp; Rheumatism,</i></span> demonstrate that combination therapy with etanercept and methotrexate over two years achieved radiographic remission<a style='mso-footnote-id:ftn1' href="#_ftn1" name="_ftnref1" title=""><span class=MsoFootnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:12.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA'>[1]</span></span><![endif]></span></span></a><span class=MsoFootnoteReference><span lang=EN-GB style='mso-fareast-font-family: "Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'>[i]</span></span> in 90 per cent of evaluable subjects with early active rheumatoid arthritis (RA)<span style='mso-bidi-font-family:Arial;mso-bidi-font-weight:bold'>, <sup>1</sup> The results also showed that the combination therapy leads to a reduction in joint pain and swelling to achieve clinical remission<a style='mso-footnote-id: ftn2' href="#_ftn2" name="_ftnref2" title=""><span class=MsoFootnoteReference><span style='mso-bidi-font-family:Arial'><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:12.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:Arial; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA; mso-bidi-font-weight:bold'>[2]</span></span><![endif]></span></span></span></a></span><span class=MsoFootnoteReference><span lang=EN-GB style='mso-fareast-font-family: "Times New Roman";mso-bidi-font-family:Arial;mso-ansi-language:EN-GB; mso-fareast-language:EN-GB;mso-bidi-font-weight:bold'>[ii]</span></span><span style='mso-bidi-font-family:Arial;mso-bidi-font-weight:bold'> in 57 per cent, and functional remission<a style='mso-footnote-id:ftn3' href="#_ftn3" name="_ftnref3" title=""><span class=MsoFootnoteReference><span style='mso-bidi-font-family:Arial'><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:12.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:Arial; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA; mso-bidi-font-weight:bold'>[3]</span></span><![endif]></span></span></span></a></span><span class=MsoFootnoteReference><span lang=EN-GB style='mso-fareast-font-family: "Times New Roman";mso-bidi-font-family:Arial;mso-ansi-language:EN-GB; mso-fareast-language:EN-GB;mso-bidi-font-weight:bold'>[iii]</span></span><span style='mso-bidi-font-family:Arial;mso-bidi-font-weight:bold'> in 62 per cent, of evaluable subjects with early active rheumatoid arthritis. <u2:p></u2:p></span><o:p></o:p></p> <p class=MsoNormal style='line-height:200%'><span style='mso-bidi-font-weight: bold'><u2:p>&nbsp;</u2:p></span></p> <p class=MsoNormal style='line-height:200%'>The COMET trial (<u>Co</u>mbination of <u>M</u>ethotrexate and <u>ET</u>anercept in Early Rheumatoid Arthritis) is the first major study of early RA with a biologic to use clinical remission as a primary endpoint and to evaluate the effects of etanercept on two additional key measures of remission: radiographic non-progression and physical function. <span style='mso-bidi-font-family:Arial;mso-bidi-font-weight:bold'><span style='mso-spacerun:yes'> </span><u2:p></u2:p></span><o:p></o:p></p> <p class=MsoNormal style='line-height:200%'><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal style='line-height:200%'><span style='mso-bidi-font-family: Arial;mso-bidi-font-weight:bold'>The two-year results from COMET demonstrate that continuous combination therapy with etanercept and methotrexate for 24 months leads to a significantly higher proportion of subjects achieving radiographic non-progression when compared to the other treatment arms.</span><span style='mso-bidi-font-family:Arial'> However, adding in etanercept after one year of methotrexate monotherapy also results in a reduced rate of radiographic progression, but this is not as great as when subjects are treated early with etanercept and methotrexate combination therapy.</span><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:200%'><i style='mso-bidi-font-style:normal'><u2:p>&nbsp;</u2:p></i></p> <p class=MsoNormal style='line-height:200%'><i style='mso-bidi-font-style:normal'> These results are important not only for patients but also may set the standard for the way physicians manage rheumatoid arthritis overall, </i> says Professor Paul Emery, lead COMET trial investigator and Professor of Rheumatology, University of Leeds, UK. <i style='mso-bidi-font-style:normal'> This study proposes a new therapeutic window of opportunity in which early treatment of rheumatoid arthritis with anti-TNF agents may not only modify the underlying disease processes, but halt the destruction of joints, and prevent joint damage from getting worse over time. <u2:p></u2:p></i><o:p></o:p></p> <p class=MsoNormal style='line-height:200%'><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal style='line-height:200%'>The COMET trial is a double-blind, randomised, multinational, two-year study which enrolled 542 patients with active early RA. <span style='mso-bidi-language:NE'>The trial consisted of two 12-month treatment periods, with patients randomised into the following four groups: 1) etanercept 50 mg plus methotrexate for 24 months; 2) combination therapy for 12 months followed by etanercept alone for 12 months; 3) methotrexate alone for 12 months followed by combination therapy for 12 months; 4) methotrexate for 24 months.</span><sup><span style='mso-fareast-font-family: "MS Mincho";mso-bidi-font-family:Shaker2Lancet-Bold;mso-fareast-language:JA; mso-bidi-language:NE'>1</span></sup><span style='mso-bidi-language:NE'><span style='mso-spacerun:yes'>  </span></span><span style='mso-bidi-font-family: Univers-CondensedLight;mso-bidi-language:NE'>The two-year data build on the one-year results, previously published in <i>The Lancet</i></span><span style='mso-fareast-font-family:"MS Mincho";mso-bidi-font-family:Shaker2Lancet-Bold; mso-fareast-language:JA;mso-bidi-language:NE'>.<sup>2 </sup></span><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:200%'><u2:p>&nbsp;</p> </u2:p> <p class=MsoNormal style='line-height:200%'>Combination therapy continued to be well tolerated with no new safety signals throughout the two years. The most common adverse events reported throughout the trial were consistent with other RA clinical trials of etanercept and included<span style='mso-bidi-font-family: Arial'> injection site reaction, infection, and headache.</span><span style='mso-spacerun:yes'>  </span>Similar to the one-year data, <span style='mso-bidi-font-family:Arial'>there were no differences in rates of serious infections or malignancies among patients in the etanercept plus methotrexate group compared with the methotrexate-only group after two years.<span style='mso-spacerun:yes'>  </span>No cases of tuberculosis or demyelinating disease were reported.<u2:p></u2:p></span><o:p></o:p></p> <p class=MsoNormal style='line-height:200%'><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal style='line-height:200%'>Rheumatoid arthritis is a chronic inflammatory disease that affects millions of people worldwide, and may get worse over time if not treated effectively, causing permanent damage to joints, deformity, loss of independence and work disability. Previous o<span style='mso-bidi-font-style:italic'>ne-year results from COMET found that </span><span style='mso-bidi-font-family:Arial;mso-bidi-font-style:italic'>RA patients receiving </span><span style='mso-bidi-font-family:Arial'>combination therapy were nearly three times less likely to stop working when compared to patients who received methotrexate alone.</span><sup>3</sup><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:200%'><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal style='line-height:200%'>Professor Emery concludes: <i style='mso-bidi-font-style:normal'> T<span style='mso-bidi-font-style:italic'>he COMET study shows that</span> early and sustained intensive therapy with etanercept can improve future outcomes for those with early rheumatoid arthritis, without posing an additional safety risk<span style='mso-bidi-font-style: italic'>. By stopping the progression of the disease early and preventing permanent joint damage, patients with RA may avoid the potential limitations of their disease. </span></i></p> <u2:p></u2:p> <p class=MsoNormal align=center style='text-align:center;line-height:200%'>-Ends-<o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal style='line-height:150%'><u2:p>&nbsp;</u2:p><o:p></o:p></p> <p class=MsoNormal style='line-height:150%'><b><u2:p>&nbsp;</u2:p></b><o:p></o:p></p> <p class=MsoNormal style='line-height:150%'><b><u2:p>&nbsp;</u2:p></b><o:p></o:p></p> <p class=MsoNormal style='line-height:150%'><b><u2:p>&nbsp;</u2:p></b><o:p></o:p></p> <p class=MsoNormal style='line-height:150%'><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal style='line-height:150%'><b>For further information, please contact: </b><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal><b>Pfizer:</b></p> <u2:p></u2:p> <p class=MsoNormal>Fanny La Monica </p> <u2:p></u2:p> <p class=MsoNormal>Direct Tel: +39 06 331 824 52</p> <u2:p></u2:p> <p class=MsoNormal>Mob: +39 335 369 827</p> <u2:p></u2:p> <p class=MsoNormal>Email: <a href="mailto:fanny.lamonica@pfizer.com">fanny.lamonica@pfizer.com</a><o:p></o:p></p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal>Carla Capobianco, </p> <u2:p></u2:p> <p class=MsoNormal>Direct Tel: +39 06 331 824 59</p> <u2:p></u2:p> <p class=MsoNormal>Mob: +39 335 8498 165</p> <u2:p></u2:p> <p class=MsoNormal>Email: <a href="mailto:carla.capobianco@pfizer.com">carla.capobianco@pfizer.com</a><o:p></o:p></p> <p class=MsoNormal><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal><b>OgilvyHealthPR: </b></p> <u2:p></u2:p> <p class=MsoNormal>Nerea Hinzpeter<span style='mso-tab-count:1'>         </span></p> <u2:p></u2:p> <p class=MsoNormal>Tel: + 44 207 108 6077</p> <u2:p></u2:p> <p class=MsoNormal>Email: <a href="mailto:nerea.hinzpeter@ohpr.com">nerea.hinzpeter@ohpr.com</a><span style='mso-tab-count:3'>                            </span><span style='mso-tab-count:1'>            </span><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</p> </u2:p> <p class=MsoNormal><b><u>References </u></b></p> <u2:p></u2:p> <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;tab-stops: list 14.2pt'><span class=src1><span style='font-size:9.5pt'>1.</span></span><span class=src1><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style='font-size:9.5pt;mso-bidi-font-family:Arial'>Emery P </span><i><span style='font-size:9.5pt'>et al</span></i><span style='font-size:9.5pt; mso-bidi-font-family:Arial'>. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy vs. monotherapy in early rheumatoid arthritis.<span style='mso-spacerun:yes'>  </span><span class=jrnl><i><span style='mso-bidi-font-family:Arial'>Arthritis Rheum</span></i></span><span class=src1><span style='mso-bidi-font-family:Arial'>. DOI 10.1002/art.27268 [E-pub ahead of print, 25 February 2010]<u2:p></u2:p></span></span></span></p> <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;tab-stops: list 14.2pt'><span style='font-size:9.5pt'>2.</span><span style='font-size: 7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:9.5pt;mso-bidi-font-family: Arial'>Emery P </span><i>et al</i><span style='font-size:9.5pt;mso-bidi-font-family: Arial'>. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet</i> 2008; 372:375-382.<u2:p></u2:p></span></p> <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;tab-stops: list 14.2pt'><span style='font-size:9.5pt'>3.</span><span style='font-size: 7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:9.5pt;mso-bidi-font-family: Arial'>Anis A <i>et al</i>. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. <i>Rheumatology</i> 2009 Oct;48(10):1283-9. E-Pub, 18 August 2009.<u2:p></u2:p></span></p> <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;tab-stops: list 14.2pt'><span style='font-size:9.5pt'>4.</span><span style='font-size: 7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:9.5pt;mso-bidi-font-family: Arial;mso-bidi-font-weight:bold'>Enbrel EMEA SPC. <a href="http://globalmessaging2.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=6517197&amp;adr_order=293&amp;url=aHR0cDovL3d3dy5lbWEuZXVyb3BhLmV1L2h1bWFuZG9jcy9QREZzL0VQQVIvRW5icmVsL2VtZWEt%0AY29tYmluZWQtaDI2MmVuLnBkZg%3D%3D"><b><span style='color:red'>MailScanner has detected a possible fraud attempt from &quot;globalmessaging2.prnewswire.com&quot; claiming to be</span></b> http://www.ema.europa.eu/humandocs/PDFs/EPAR/Enbrel/emea-combined-h262en.pdf</a> </span><span style='font-size:9.5pt;mso-bidi-font-family:Arial'><span style='mso-spacerun:yes'> </span><span style='mso-bidi-font-weight:bold'>Last accessed February 2010.<u2:p></u2:p></span></span><o:p></o:p></p> <p class=MsoNormal><b><u2:p>&nbsp;</b></p> </u2:p> <p class=MsoNormal><b><u>Notes to editors</u></b><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal><b>About the COMET Trial</b></p> <u2:p></u2:p> <p class=MsoNormal>The COMET (<u>CO</u>mbination of <u>M</u>ethotrexate and <u>ET</u>anercept in early rheumatoid arthritis) trial was designed to compare the clinical efficacy and safety of etanercept and methotrexate combination therapy (EM) with methotrexate alone (M) on clinical disease activity and progressive joint damage in patients with early active rheumatoid arthritis. COMET is the first major study to use clinical remission as a primary endpoint.<o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal><b>About ENBREL<sup>4</sup></b></p> <u2:p></u2:p> <p class=MsoNormal>ENBREL is a fully human soluble tumour necrosis factor (TNF) receptor antagonist.<span style='mso-spacerun:yes'>  </span>ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in 505,000 patients worldwide across indications. <o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal>For full information about ENBREL go to: <a href="http://globalmessaging2.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=6517197&amp;adr_order=293&amp;url=aHR0cDovL3d3dy5lbWEuZXVyb3BhLmV1"><b><span style='color:red'>MailScanner has detected a possible fraud attempt from &quot;globalmessaging2.prnewswire.com&quot; claiming to be</span></b> www.ema.europa.eu</a><u2:p></u2:p><o:p></o:p></p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal>ENBREL is approved for the following indications:<o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal><b>Rheumatoid arthritis</b></p> <u2:p></u2:p> <p class=MsoNormal>ENBREL in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. ENBREL can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.<span style='mso-spacerun:yes'>  </span>ENBREL is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. ENBREL, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. <o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal><b>Polyarticular juvenile idiopathic arthritis</b></p> <u2:p></u2:p> <p class=MsoNormal>Treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 4 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. ENBREL has not been studied in children aged less than 4 years. <o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p><o:p></o:p></p> <p class=MsoNormal><u2:p>&nbsp;</u2:p><o:p></o:p></p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal><b>Psoriatic arthritis</b></p> <u2:p></u2:p> <p class=MsoNormal>Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. ENBREL has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. <o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal><b>Ankylosing spondylitis</b></p> <u2:p></u2:p> <p class=MsoNormal>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. <o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><b><u2:p>&nbsp;</u2:p></b></p> <p class=MsoNormal><b>Plaque psoriasis</b></p> <u2:p></u2:p> <p class=MsoNormal>Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A-light (PUVA).<span style='mso-spacerun:yes'>  </span>ENBREL is also licensed in the European Union for treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.<o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal><b>Pfizer Inc: Working together for a healthier world</b></p> <u2:p></u2:p> <p class=MsoNormal>At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.<span style='mso-spacerun:yes'>  </span>We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.<span style='mso-spacerun:yes'>  </span>Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.<span style='mso-spacerun:yes'>  </span>Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.<span style='mso-spacerun:yes'>  </span>For more than 150 years, Pfizer has worked to make a difference for all who rely on us.<span style='mso-spacerun:yes'>  </span>To learn more about our commitments, please visit us at <a href="http://globalmessaging2.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=6517197&amp;adr_order=293&amp;url=aHR0cDovL3d3dy5wZml6ZXIuY29t"><b><span style='color:red'>MailScanner has detected a possible fraud attempt from &quot;globalmessaging2.prnewswire.com&quot; claiming to be</span></b> www.pfizer.com</a></p> <u2:p></u2:p> <p class=MsoNormal><span style='mso-spacerun:yes'> </span></p> <u2:p></u2:p> <p class=MsoNormal>Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations.</p> <u2:p></u2:p> <p class=MsoNormal><span style='mso-spacerun:yes'> </span></p> <u2:p></u2:p> <p class=MsoNormal>More information is available at <a href="http://globalmessaging2.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=6517197&amp;adr_order=293&amp;url=aHR0cDovL3d3dy5wZml6ZXIuY29t"><b><span style='color:red'>MailScanner has detected a possible fraud attempt from &quot;globalmessaging2.prnewswire.com&quot; claiming to be</span></b> www.pfizer.com</a>. <span style='mso-spacerun:yes'> </span><o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <p class=MsoNormal>Follow Pfizer on <a href="http://globalmessaging2.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=6517197&amp;adr_order=293&amp;url=aHR0cDovL3d3dy50d2l0dGVyLmNvbS9wZml6ZXJfbmV3cw%3D%3D"><b><span style='color:red'>MailScanner has detected a possible fraud attempt from &quot;globalmessaging2.prnewswire.com&quot; claiming to be</span></b> www.Twitter.com/pfizer_news</a>.<o:p></o:p></p> <u2:p></u2:p> <p class=MsoNormal><u2:p>&nbsp;</u2:p><o:p></o:p></p> <p class=MsoNormal><u2:p>&nbsp;</u2:p></p> <div> <p class=MsoNormal><span style='mso-fareast-font-family:"Times New Roman"'><br clear=all style='mso-special-character:line-break'> <o:p></o:p></span></p> <div class=MsoNormal><span style='mso-fareast-font-family:"Times New Roman"'> <hr size=1 width="33%" align=left> </span></div> </div> <p class=MsoNormal><span style='mso-fareast-font-family:"Times New Roman"'><img border=0 id="_x0000_i1026" src="http://www.mailscanner.tv/1x1spacer.gif" alt="Web Bug from http://globalmessaging2.prnewswire.com/servlet/faxtrack?action=url_pull_tracking&amp;MSGID=6517197&amp;RCP_ORDER=293"><o:p></o:p></span></p> </div> <div style='mso-element:footnote-list'><![if !supportFootnotes]><br clear=all> <hr align=left size=1 width="33%"> <![endif]> <div style='mso-element:footnote' id=ftn1> <p class=MsoFootnoteText style='margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-indent:-7.1pt'><a style='mso-footnote-id:ftn1' href="#_ftnref1" name="_ftn1" title=""><span class=MsoFootnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:12.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA'>[1]</span></span><![endif]></span></span></a><span class=MsoFootnoteReference><span lang=EN-GB style='font-size:10.0pt;font-family: "Arial","sans-serif";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: "Times New Roman";mso-ansi-language:EN-GB'>[i]</span></span><span lang=EN-GB style='font-size:10.0pt'> </span><span style='font-size:9.0pt'>Radiographic non-progression as measured by the change in <a name="OLE_LINK8">the <span style='mso-font-kerning:14.0pt'>modified Total Sharp Score</span> (mTSS) d"0.5</a><u2:p></u2:p></span><span style='mso-bookmark:OLE_LINK8'></span></p> </div> <div style='mso-element:footnote' id=ftn2> <p class=MsoFootnoteText style='margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-indent:-7.1pt'><a style='mso-footnote-id:ftn2' href="#_ftnref2" name="_ftn2" title=""><span class=MsoFootnoteReference><span style='font-size:9.0pt'><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:9.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA'>[2]</span></span><![endif]></span></span></span></a><span class=MsoFootnoteReference><span lang=EN-GB style='font-size:9.0pt;font-family: "Arial","sans-serif";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: "Times New Roman";mso-ansi-language:EN-GB'>[ii]</span></span><span style='font-size:9.0pt'> The number of <span style='mso-font-kerning:14.0pt'>subjects achieving DAS28 remission (DAS </span></span><span style='font-size:9.0pt; mso-bidi-font-family:Arial;mso-font-kerning:14.0pt'>d"2.6</span><span style='font-size:9.0pt;mso-font-kerning:14.0pt'>)</span></p> <u2:p></u2:p></div> <div style='mso-element:footnote' id=ftn3> <p class=MsoFootnoteText style='margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-indent:-7.1pt'><a style='mso-footnote-id:ftn3' href="#_ftnref3" name="_ftn3" title=""><span class=MsoFootnoteReference><span style='font-size:9.0pt'><span style='mso-special-character:footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span style='font-size:9.0pt;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA'>[3]</span></span><![endif]></span></span></span></a><span class=MsoFootnoteReference><span lang=EN-GB style='font-size:9.0pt;font-family: "Arial","sans-serif";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: "Times New Roman";mso-ansi-language:EN-GB'>[iii]</span></span><span lang=EN-GB style='font-size:9.0pt'> </span><span style='font-size:9.0pt;mso-font-kerning: 14.0pt'>Functional improvement was measured using the Health Assessment Questionnaire Disability Index (HAQ-DI), and the proportion of subjects in each group who achieved normal HAQ-DI [0.5 or less] was evaluat</span><span style='font-size:10.0pt;mso-font-kerning:14.0pt'>ed.</span><u2:p></u2:p></p> </div> </div> </body> </html>